LIVE MARKET TRACKER :   BSE SENSEX        |    NSE NIFTY    
GLOBAL MARKETS :  NASDAQ      |    FSI London      |    NIKKEI Japan  
  USD GBP EUR CAD AUD INR
USD -
GBP -
EUR -
CAD -
AUD -
INR -
Indian-Commodity  :  Equity & Shares  :  Lupin gains on receiving FDA approval for Potassium Chloride Extended Release Capsules

Lupin gains on receiving FDA approval for Potassium Chloride Extended Release Capsules (18-Aug-2016)

Lupin is currently trading at Rs. 1597.20, up by 1.90 points or 0.12% from its previous closing of Rs. 1595.30 on the BSE.

The scrip opened at Rs. 1598.00 and has touched a high and low of Rs. 1607.65 and Rs. 1591.50 respectively. So far 34,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2127.00 on 06-Oct-2015 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.

Last one week high and low of the scrip stood at Rs. 1607.65 and Rs. 1568.50 respectively. The current market cap of the company is Rs. 72,030.00 crore.

The promoters holding in the company stood at 46.76%, while Institutions and Non-Institutions held 42.40% and 10.83% respectively.

Lupin's US subsidiary, Gavis Pharmaceuticals LLC., USA (collectively Lupin) has received final approval for its Potassium Chloride Extended Release Capsules USP, 8 mEq (600 mg) and 10 mEq (750 mg) from the United States Food and Drug Administration (FDA) to market a generic equivalent of Actavis Labs FL, Inc's Potassium Chloride Extended Release Capsules USP, 8 mEq and 10 mEq. Potassium Chloride Extended Release Capsules USP, 8 mEq and 10 mEq had US sales of USD 75.4 million as per IMS MAT March 2016 data.

Lupin's Potassium Chloride Extended Release Capsules USP, 8 mEq (600 mg) and 10 mEq (750 mg) are the AB rated generic equivalent of Actavis Labs FL, Inc's Potassium Chloride Extended Release Capsules USP, 8 mEq and 10 mEq. It is indicated for the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications and in patients with hypokalemic familial periodic paralysis. It is also indicated for the prevention of hypokalemia in patients who would be at a particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally.





Top News Today
Reliance Nippon Life Insurance's total premium rises to Rs 4,042 crore in FY18
(23-Apr-2018)

Reliance Nippon Life InsuranceReliance Capital's subsidiary -- Reliance Nippon Life Insurance Company has reported a the total premium of Rs 4,042 crore ($622 million) in FY18. The renewal premium rose to Rs 3,154 crore ($485......click on news to read complete article.

Gujarat Ambuja Exports starts commercial operations of first phase of green field plant
(23-Apr-2018)

Gujarat Ambuja Exports starts commercial operations of first phase of green field plantGujarat Ambuja Exports has commenced the commercial operations of first phase of its 1000 MT per day green field Maize processing plant set up at Chalisgaon in Maharashtra. This marks the completion of......click on news to read complete article.

KPIT partners with Indian Government to support first Smart India Hackathon 2018
(23-Apr-2018)

KPIT partners with Indian Government to support first Smart India Hackathon 2018KPIT Technologies has partnered with the Indian Government to support the first Smart India Hackathon 2018 - Hardware Edition. KPIT, which brings expertise in developing clean, green and intelligent technologies......click on news to read complete article.

International Stock News
Asian markets trade mostly in red in early deals on Monday
(23-Apr-2018)

Asian markets trade mostly in red in early deals on MondayMost of the Asian equity indices are trading lower in the early deals on Monday, following the negative lead from Wall Street on Friday as technology stocks declined. Investors are cautious as they kept......click on news to read complete article.

US markets closed lower on Friday
(21-Apr-2018)

US markets closed lower on FridayThe US markets closed lower on Friday, as weakness in technology and consumer staples shares offset the latest batch of corporate earnings, which largely continued to beat expectations. The selling pressure......click on news to read complete article.

US markets closed lower on Friday
(21-Apr-2018)

US markets closed lower on FridayThe US markets closed lower on Friday, as weakness in technology and consumer staples shares offset the latest batch of corporate earnings, which largely continued to beat expectations. The selling pressure......click on news to read complete article.

 

     
  
Recent Equity & Shares News
 
EquityInvestmentCompany ReportsIPO
Disclaimer
By clicking on this page you accept all the terms and conditions framed by us. News made available here are for informational purpose only. While utmost care has been taken in providing the same. We claim no responsibility for its accuracy. Readers of this blog who make their decision based on the information posted here are solely responsible for their actions.